Peptides for Bipolar Disorder: New Avenues for Mood Stabilization

Written by Adam Maggio | Medically reviewed by Dr. James Whitfield, DO, FACOI

Bipolar disorder involves significant mood shifts. GLP-1 agonists show promise but require caution due to potential mood destabilization. VGF peptides are being investigated as diagnostic biomarkers, and NPY may enhance stress resilience.

Peptides for Bipolar Disorder

Bipolar disorder is a complex mood disorder characterized by significant shifts in mood, energy, activity levels, and concentration. These shifts can range from periods of elevated mood (mania or hypomania) to periods of profound depression. Managing bipolar disorder often involves a combination of mood stabilizers, antipsychotics, and psychotherapy. However, research into novel therapeutic approaches, including the use of peptides, is gaining traction, offering potential new avenues for symptom management and understanding the disorder's underlying neurobiology.

GLP-1 Receptor Agonists: A Double-Edged Sword?

Glucagon-Like Peptide-1 (GLP-1) receptor agonists, widely known for their roles in diabetes and weight management, are emerging as a fascinating area of study in bipolar disorder. These peptides have been shown to modify large-scale brain networks involved in emotion regulation, motivation, and cognition—networks often dysregulated in bipolar disorder. A narrative review by Llach et al. (2026) discusses preclinical and clinical evidence suggesting their potential as emerging therapeutics.

However, it's crucial to approach GLP-1 agonists with caution in bipolar patients. Clinical observations and some reports suggest that these medications can potentially trigger or heighten mood changes, particularly manic or hypomanic episodes. Unlike their generally beneficial effects in unipolar depression, their impact on the delicate balance of bipolar mood states requires careful consideration and close monitoring by a clinician. This highlights the importance of individualized treatment plans and understanding the nuanced effects of peptides on different mental health conditions.

VGF Peptides: Potential Biomarkers for Diagnosis

Beyond treatment, peptides are also being investigated for their diagnostic potential. VGF (non-acronymic) peptides, specifically AQEE-14 and NAPP-19, have shown promise as potential biomarkers for bipolar disorder. Research by Cocco et al. (2024) found that plasma levels of these VGF peptides differ significantly in patients with bipolar disorder compared to healthy controls and individuals with other mood disorders. Lower levels of NAPP and AQEE were specifically associated with bipolar disorder.

This finding is significant because it suggests that these peptides could one day aid in the objective diagnosis of bipolar disorder, which can often be challenging due to its varied presentation and overlap with other conditions. Unlike subjective symptom reporting, a biomarker could provide a more definitive diagnostic tool, leading to earlier and more accurate interventions.

Neuropeptide Y (NPY): A Link to Resilience

Neuropeptide Y (NPY), a peptide neurotransmitter involved in stress regulation, has also been implicated in bipolar disorder. Studies have indicated that individuals with bipolar disorder often have lower NPY levels compared to those with major depressive disorder. This suggests a potential role for NPY in the pathophysiology of bipolar disorder, possibly contributing to differences in stress resilience and mood stability. While direct NPY supplementation for bipolar disorder is not yet a standard treatment, understanding its role can inform future research into therapeutic strategies that aim to enhance stress coping mechanisms.

Practical Takeaway

The role of peptides in bipolar disorder is an exciting and evolving area of research. While GLP-1 agonists show promise, their use requires careful clinical oversight due to the potential for mood destabilization. VGF peptides offer a glimpse into future diagnostic tools, and NPY research may lead to new insights into resilience. It's vital for individuals with bipolar disorder to work closely with their healthcare providers to develop a comprehensive treatment plan. Any consideration of peptide therapies should be undertaken with a clear understanding of the current evidence, potential risks, and under the guidance of a clinician experienced in both bipolar disorder and peptide applications. Self-medication with peptides for bipolar disorder is strongly discouraged due to the complexity of the condition and the need for precise medical management.